

Ref no: 148191119
From: Commercial
Date: 19/11/19
Subject: Juvenile ideopathic arthritis

REQUEST

I would like to understand how patients with juvenile ideopathic arthritis are being treated. So, in the last 6 months, how many patient(s) with juvenile ideopathic arthritis have been treated with:

Humira (adalimumab)
Amgevita (adalimumab)
Imraldi (adalimumab)
Hyrimoz (adalimumab)
Hulio (adalimumab)
Tocilizumab
Abatacept
Enbrel (etanercept)
Erelzi (etanercept)
Benepali (etanercept)
Golimumab
Remicade (infliximab)
Remsima (infliximab)
Inflectra (infliximab)
Flixabi (infliximab)
Canakinumab
Anakinra

RESPONSE

The Trust does not hold this information in this format. Patients are identifiable by diagnosis; medication prescribed is coded in relation to these patients. A manual exercise exceeding cost* would be required to identify patients treated with this medication in relation to this specific diagnosis.

***Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a request if we estimate that the cost of complying with your request would exceed the appropriate limit of £450. The**

appropriate limit has been specified in regulations. This represents the estimated cost of one person spending 2½ working days (18 hours) in answering the remainder of your questions. Under section 12 of the Freedom of Information Act the Department is not obliged to comply with your request and we will not be processing your request further.